Scancell Holdings (GB:SCLP) has released an update.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Scancell Holdings has announced that Genmab has exercised its option for a second commercial license agreement, granting Genmab exclusive rights to develop and commercialize a monoclonal antibody from Scancell’s GlyMab® platform. This move could potentially yield Scancell up to $630 million in milestone payments and royalties from net sales. This strategic partnership highlights Scancell’s innovative approach in developing therapeutics targeting cancer-specific glycans.
For further insights into GB:SCLP stock, check out TipRanks’ Stock Analysis page.
